Inactief instrument

Andere talen NanoViricides Inc OTC Bulletin Board

Aandelen

US6300871042

slotkoers OTC Bulletin Board Andere beurzen
- ^USD	-

12:30	Nanoviriciden, Inc. NanoViricides meldt dat haar in klinische fase verkerende nanoviricide breed-spectrum antivirale kandidaat, NV-387, oraal toegediend, resulteert in een ideaal vlak bloedconcentratieprofiel voor een aanhoudend antiviraal effect.	CI
04/06	NanoViricides, Inc. NanoViricides rapporteert over het zeer wenselijke bloedconcentratieprofiel van zijn belangrijkste klinische breed-spectrum antiviraal middel NV-387 na intraveneuze toediening	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Nanoviricides, Inc. Reports Clinical Stage Lead Nanoviricide Broad-Spectrum Antiviral Drug Candidate Orally Administered Nv-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect	12:30
NanoViricides - The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect, A First-In-Class, Broad-Spectrum Antiviral Agent	05/06
NanoViricides, Inc. Reports on the Highly Desirable Blood Concentration Profile of its Lead Clinical Stage Broad-Spectrum Antiviral Agent NV-387 Upon Intravenous	04/06
NanoViricides, Inc. - A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More, Novel Host-Mimetic, Virus Killing Technology Platform	30/05
NanoViricides, Inc. Intends to Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More	29/05
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results	29/05
NanoViricides Has Filed its Quarterly Report, NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection	16/05
NanoViricides, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	15/05
NanoViricides: Fiscal Q3 Earnings Snapshot	15/05
NanoViricides, Inc. Announces A Novel Broad-Spectrum Antiviral with Activity Against RSV	14/05
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference on May 15 in New York City	13/05
NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox	08/05
NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Influenza A	06/05
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon	01/05
NanoViricides, Inc. Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon	30/04
NanoViricides: Fiscal Q2 Earnings Snapshot	14/02
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14/02
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications beyond COVID Treatment, Explains NanoViricides, NV-387 Could be As Revolutionary as Antibiotics	02/02
NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics	01/02
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides	30/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen NanoViricides Inc OTC Bulletin Board

Aandelen

US6300871042

Andere talen

Filters